본문 바로가기

EU · EudraLex Vol.4

EU GMP Part I, Chapter 1

Pharmaceutical Quality System

Status of the document: revision 3

조항 목차

  1. PrinciplePrinciple
  2. 1.1Quality Management is a wide-ranging concept, which covers all matters, which individually or collectively influence the quality of a produ…
  3. 1.2GMP applies to the lifecycle stages from the manufacture of investigational medicinal products, technology transfer, commercial manufacturi…
  4. 1.3The size and complexity of the company’s activities should be taken into consideration when developing a new Pharmaceutical Quality System…
  5. 1.4A Pharmaceutical Quality System appropriate for the manufacture of medicinal products should ensure that: (i) Product realisation is achiev…
  6. 1.5Senior management has the ultimate responsibility to ensure an effective Pharmaceutical Quality System is in place, adequately resourced an…
  7. 1.6There should be periodic management review, with the involvement of senior management, of the operation of the Pharmaceutical Quality Syste…
  8. 1.7The Pharmaceutical Quality System should be defined and documented. A Quality Manual or equivalent documentation should be established and…
  9. 1.8Good Manufacturing Practice is that part of Quality Management which ensures that products are consistently produced and controlled to the…
  10. 1.9Quality Control is that part of Good Manufacturing Practice which is concerned with sampling, specifications and testing, and with the orga…
  11. 1.10Regular periodic or rolling quality reviews of all authorised medicinal products, including export only products, should be conducted with…
  12. 1.11The manufacturer and, where different, marketing authorisation holder should evaluate the results of the review and an assessment made as t…
  13. 1.12Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the medici…
  14. 1.13The principles of quality risk management are that: i) The evaluation of the risk to quality is based on scientific knowledge, experience w…
표지·목차 원문

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Health Systems and Products Medicinal Products - Quality, safety and efficacy

Brussels, SANCO/AM/sl/ddg1.d.6(2012)860362

EudraLex

The Rules Governing Medicinal Products in the European Union

Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use

Chapter 1 Pharmaceutical Quality System

Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use.

Status of the document: revision 3

Reasons for changes: Amendments to the text of Chapter 1 have been made in order to align with the concepts and terminology described in the ICH Q10 tripartite guideline on Pharmaceutical Quality System. The title of the chapter itself is also changed accordingly.

Deadline for coming into operation: 31 January 2013

Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel – Belgium. Telephone: (32-2) 299 11 11

출처: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · 수집일 2026-11-15

Weekly Newsletter

이런 지적, 매주 월요일 한국어로 받아보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

매주 월요일 발송 · 구독 신청 시 확인 메일이 발송됩니다 · 수신거부는 모든 메일 하단에서 가능합니다.